A fluorescence probe with mitochondrial targeting and two-photon property, its preparation method and application in detecting and tracking endogenous H.sub.2S in samples or living cells. The fluorescent probe is prepared by a four-step preparation method and demonstrates a UV-vis absorption increment .sub.ab=395 nm and 43 fold higher fluorescence intensity in the presence of H.sub.2S. The probe further demonstrates stability, selectivity for H.sub.2S over competing agents and sensitivity as low as 20 nm. A method of detecting endogenous H.sub.2S rapidly in the absence of any external stimulators is provided. Samples are contacted with the probe and the changes in fluorescence are monitored to detect H.sub.2S levels. The disclosed probe is non-toxic and suitable as a biomarker and therapeutic molecule in cancer and other diseases.

Novel heterocyclic selenamonophosphites protected on the hydroxyl group, processes for preparation thereof and the use thereof as ligand.

Novel heterocyclic selenabisphosphites, process for preparation thereof and use thereof as ligand unit for preparing ligands for use in complexes.

The present application provides a compound that inhibits TRAP1 or a pharmaceutically acceptable salt thereof. In this case, the compound or the pharmaceutically acceptable salt thereof can inhibit the binding between TRAP1 and the client protein. In addition, the present application provides: a pharmaceutical composition for the treatment of cancer or ocular disease comprising a compound that inhibits TRAP1 or a pharmaceutically acceptable salt thereof; and use thereof.

The present invention relates to an electrically doped semiconducting material comprising at least one metallic element as n-dopant and at least one electron transport matrix compound comprising at least one phosphine oxide group, a process for its preparation, and an electronic device comprising the electrically doped semiconducting material.

Compounds of formula I are disclosed:

##STR00001##

wherein X.sup.1, X.sup.2, X.sup.3, X.sup.4 are independently H, F, Cl, Br, I, CN, NO.sub.2, OR.sup.1, SR.sup.1, NR.sup.1R.sup.2, COR.sup.1, COOR.sup.1, CONR.sup.1R.sup.2, PO.sub.3R.sup.1R.sup.2, SO.sub.2R.sup.1, SO.sub.3R.sup.1 or R.sup.3; R.sup.1 and R.sup.2 are, e.g., H, alkyl or aryl or optionally a ring; R.sup.3 is, e.g., alkyl, alkenyl, alkynyl, aryl or cycloalkyl; Y is OR.sup.1, NR.sup.1R.sup.2, or NR.sup.1R.sup.3; Q is O, S, SO.sub.2, NR, C(R.sup.3).sub.2, Si(R.sup.3).sub.2, Ge(R.sup.3).sub.2, P(O)R.sup.3 or P(O)OR.sup.3; Q and X.sup.1 can optionally form part of a ring; L and M are independently OR.sup.1, SR.sup.1, NR.sup.1R.sup.2 and R.sup.3; L and M can optionally form part of a ring; Z is O, S, NR.sup.1, CR.sup.1R.sup.3 or aryl; and Z and X.sup.4 can optionally form part of a ring.

Described herein are ?.sup.9-THC prodrugs, methods of making ?.sup.9-THC prodrugs, formulations comprising ?.sup.9-THC prodrugs and methods of using ?.sup.9-THC. One embodiment described herein relates to the transdermal administration of a ?.sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.

The present disclosure is directed to fluorogenic schiff base-forming dyes capable of detecting analytes containing aldehyde and ketone groups. The dyes contain nucleophilic hydrazinyl appendages and are capable of binding and detecting analytes in situ.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6, M.sup.1, M.sup.2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

##STR00001##